Video Series

Individualizing First-Line Immunotherapy in Advanced cSCC: Selecting a PD-1 vs PD-L1 Strategy

10/21/2026

Round 1

How Should Pivotal Trial Data Guide First-Line Treatment Selection?

In a fit, treatment-naive patient with good performance status, does the mature, multi-year efficacy and safety data behind anti-PD-1 agents outweigh the rationale for a newer, selective anti-PD-L1 option? Experts debate how follow-up maturity, trial population differences, and emerging mechanistic considerations should factor into first-line selection.

Round 2

What Tolerability Trade-Offs Exist and How Do They Shape Real-World Use?

For an older, comorbid patient where a steroid-requiring adverse event could carry outsized risk, how much weight should mechanistic and tolerability differences between PD-1 and PD-L1 inhibition receive in first-line systemic immunotherapy selection? Experts examine whether preserved PD-L2 signaling offers a meaningful safety advantage.

This is a non-CME activity.

The views and opinions expressed by the presenter(s) do not necessarily reflect the views and opinions of the Oncology Learning Network, HMP Global, or its employees and affiliates.

Sunandana Chandra, MD

Dr Chandra is a medical oncologist with the Robert H Lurie Comprehensive Cancer Center in Chicago, IL.

Solly Chedid, MD

Dr Chedid is a medical oncologist with the Singing River Health Care System in Ocean Springs, MS.

Bahar Dasgeb, MD

Dr Dasgeb is a dermato-oncologist with the Rutgers Cancer Institute of New Jersey.

Individualizing First-Line Immunotherapy in Advanced cSCC: Selecting a PD-1 vs PD-L1 Strategy

Round 1

How Should Pivotal Trial Data Guide First-Line Treatment Selection?

Round 2

What Tolerability Trade-Offs Exist and How Do They Shape Real-World Use?

HMP Global Products

Events